India ·
Rosewood and India Business Excellence Fund sell a ₹648cr stake in Symbiotec Pharmalab days before its IPO
Existing PE backers Rosewood Investments and India Business Excellence Fund-III sold a combined 10.4% stake in the API maker for ₹648 crore at ₹988/share — the top of the price band for its ₹1,757 crore IPO opening August 24 — to institutional buyers including Think India Opportunities, Dymon Asia, ValueQuest and WhiteOak Capital.
Source: Free Press Journal ↗
Frequently asked questions
Is this an original report, or a copy of the source article?
This is original commentary and context written for this site, citing Free Press Journal as the source. Read the full original reporting at the source link below.
How current is this information?
This item reflects reporting as of 19 August 2026. Secondary-market situations like this one can change quickly — check the source link for the latest developments.